DNA-based Bi-layered effervescent ejecting microneedle (BEE MN) for glucose-responsive insulin delivery

Area of Science:

• Biomaterials Science
• Drug Delivery Systems
• Nanotechnology

Background:

• Conventional injections face limitations in drug loading and release for chronic diseases.
• Microneedle technology offers minimally invasive alternatives but requires enhanced delivery mechanisms.

Purpose of the Study:

• To develop a novel bi-layered effervescent ejecting microneedle (BEE MN) system for enhanced transdermal drug delivery.
• To engineer a glucose-responsive system for precise, on-demand insulin administration.

Main Methods:

• Designed a dual-stage microneedle with a glucose-responsive DNA reservoir and an effervescent matrix for CO2 generation.
• Utilized rolling circle amplification (RCA) to create insulin-binding aptamer structures.
• Evaluated drug penetration, retention, and glucose-triggered release in vitro.

Main Results:

• The BEE MN system demonstrated CO2-powered self-propulsion, improving drug delivery into the dermal layer.
• Engineered DNA reservoirs enabled high-density aptamer structures for controlled insulin release.
• Achieved efficient, glucose-responsive insulin release under hyperglycemic conditions.

Conclusions:

• The CO2-powered, self-propulsive microneedle system offers enhanced transdermal drug delivery capabilities.
• This technology presents a promising platform for next-generation smart insulin delivery systems.
• The BEE MN system overcomes limitations of traditional microneedles for efficient, on-demand drug administration.